Evidence map›Paper›PMID 28152135›Full record

ArticleJAMA ophthalmology2017

Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-Reply.

Neil M Bressler, Adam R Glassman, David W Hutton

Registry-linked trialAbstract readComment
PubMed Publisher
In one paragraph

Article in JAMA ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01627249 (A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01627249 phase3completednot on this map

A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema

TypeinterventionalSponsorJaeb Center for Health ResearchRan2012 to 2019Enrolled660ConditionsDiabetic Macular EdemaArms2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Neil M BresslerWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland2Editor, JAMA Ophthalmology.
Adam R GlassmanJaeb Center for Health Research, Tampa, Florida.
David W HuttonDepartment of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor5Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor6College of Engineering, Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BevacizumabMacular EdemaAngiogenesis InhibitorsDiabetic RetinopathyHumansIntravitreal InjectionsOff-Label UseTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsBevacizumabVascular Endothelial Growth Factor A

Identifiers

PMID28152135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.